EVAX Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -0.85%, SMA50 -23.16%, SMA200 -17.66%). The stock’s 14-day RSI is 41.37 (neutral), while the ATR of 0.31 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -73.25% below its high and over 170.83% above its low. Average 10-day trading volume of 61.10 thousand shares is below the 3-month average of 193.57 thousand, indicating normal recent market interest.

Evaxion Biotech A/S generated EPS of -$5.96 over the past year. Five-year average earnings growth is 22.22%. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 7 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $16.00 to $10.00. The high target offers 386.32% upside. The low target suggests 203.95% downside. The mean target is $13.71. This offers 316.72% upside. Evaxion Biotech A/S earnings surprise history is a consistent trend of beating forecasts. The quarter that ended August 20, 2026, missed forecasts by 0.0%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include 52.0% in August 14, 2025.

Evaxion Biotech A/S (NASDAQ:EVAX) closed at $3.29 USD, gaining $0.12 (3.79%) from the previous close of $3.17. The stock is currently mid-range between its 52-week high and low $2.72 and $12.15. With a market capitalization of about $20.78 million, Evaxion Biotech A/S is classified as a micro-cap and shows lower-than-market volatility (beta ~0.27). Key stats such as the average daily volume over the past year has been around 200.19 thousand shares, volume is running light vs its 52-week average. Headquartered in Horsholm, ND, Evaxion Biotech A/S operates in the Healthcare sector and the Biotechnology industry. Led by CEO Helen Katrina Tayton-Martin, the company employs approximately 46 people and listed since February 05, 2021. Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies.

Evaxion Biotech A/S has 8.34 million shares outstanding. The public float is 5.08 million shares, elevated short interest at 0.24% of float. This equals 16.82 thousand shares. The short ratio is 1.1 days. Institutional investors hold 11.43% of the float. Insiders own 17.47%.

Evaxion Biotech A/S last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.34. This means the shares are trading below this model’s fair value.

Evaxion Biotech A/S trades at a P/E ratio of -0.53, slightly below the S&P 500 average, with a price-to-sales ratio of 2.74 and a price-to-book ratio of 0.14 suggesting the stock is closer to book value. The P/FCF stands at 0.0, also above market averages.

Evaxion Biotech A/S (NASDAQ:EVAX) shares are flat -1.89% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Evaxion Biotech A/S trading at a premium to the broader market with a P/E of -0.53. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $12.56, suggesting 281.76% upside. Our AI forecast model points to short-term weakness (-5.47% over two weeks), a medium-term rise (48.63% over three months), and a longer-term loss (-15.81% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Evaxion Biotech A/S stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.47%, with price expected at $3.11 by September 22, 2026, within a range of $2.96 to $3.27 3-Month Outlook: Projected rise of 48.63%, reaching $4.89 by December 07, 2026, with a range of $4.17 to $5.35. 1-Year Outlook: Projected loss of -15.81%, with price at $2.77 by September 08, 2027, within a range of $0.00 to $0.69.